8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Development of Screening Criteria for Retinopathy of Prematurity in Ulaanbaatar, Mongolia, Using a Web-based Data Management System

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose:

          To describe a process for identifying birth weight (BW) and gestational age (GA) screening guidelines in Mongolia.

          Methods:

          This was a prospective cohort study in a tertiary care hospital in Ulaanbataar, Mongolia, of 193 premature infants with GA of 36 weeks or younger and/or BW of 2,000 g or less) with regression analysis to determine associations between BW and GA and the development of retinopathy of prematurity (ROP).

          Results:

          As BW and GA decreased, the relative risk of developing ROP increased. The relative risk of developing any stage of ROP in infants born at 29 weeks or younger was 2.91 (95% CI: 1.55 to 5.44; P < .001] compared to older infants. The relative risk of developing any type of ROP in infants with BW of less than 1,200 g was 2.41 (95% CI: 1.35 to 4.29; P = .003] and developing type 2 or worse ROP was 2.05 (95% CI: 0.99 to 4.25; P = .05).

          Conclusions:

          Infants in Mongolia with heavier BW and older GA who fall outside of current United States screening guidelines of GA of 30 weeks or younger and/or BW of 1,500 g or less developed clinically relevant ROP.

          Related collections

          Author and article information

          Journal
          7901143
          5137
          J Pediatr Ophthalmol Strabismus
          J Pediatr Ophthalmol Strabismus
          Journal of pediatric ophthalmology and strabismus
          0191-3913
          1938-2405
          29 January 2021
          01 September 2020
          12 February 2021
          : 57
          : 5
          : 333-339
          Affiliations
          Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois (SLO, EDC, KEJ, NGV, JH, RVPC); the Center for Global Health, College of Medicine, University of Illinois at Chicago, Chicago, Illinois (SLO); National Center for Maternal and Child Health, Ulaanbaatar, Mongolia (TC, MB); Orbis International, New York, New York (CC, DHC, NC); The Hospital for Sick Children, Toronto, Ontario, Canada (LDM); Weill Cornell Medical College, New York, New York (VY); the Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon (SO, JPC, MFC); Chang Gung Memorial Hospital, Taoyuan, Taiwan (WCW); Queen’s University Belfast, Belfast, United Kingdom (NC); and Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People’s Republic of China (NC).
          Author notes

          Dr. Chiang is an unpaid member of the Scientific Advisory Board for Clarity Medical Systems (Pleasanton, CA), a consultant for Novartis (Basel, Switzerland), and an initial member of Inteleretina (Honolulu, HI). Dr. Chan is on the Scientific Advisory Board for Phoenix Technology (Pleasanton, CA) and is a consultant for Novartis (South San Francisco, CA) and Alcon Laboratories, Inc (Fort Worth, TX). The remaining authors have no financial or proprietary interest in the materials presented herein.

          Correspondence: R.V. Paul Chan, MD, 1855 W. Taylor Street, Suite 3.138, Chicago, IL 60612. rvpchan@ 123456uic.edu
          Article
          PMC7880618 PMC7880618 7880618 nihpa1666032
          10.3928/01913913-20200804-01
          7880618
          32956484
          c6b86503-8efc-4ccd-a829-a4e9898051ec
          History
          Categories
          Article

          Comments

          Comment on this article